Study Information for: "Surveillance Study of Somavert Therapy in Patients with Acromegaly" - Be Involved - CepEsperu Baptist Health

What we are studying

The goal of this outcomes study will be to continue monitoring safety but also to directly focus on clinical (symptoms and quality of life) and biochemical control (IGF-I and glucose). Specifically, data will be collected more systematically related to diabetes control and include additional data on PRO measurements. Data will be collected at baseline and at intervals in accordance with the standard management of patients with acromegaly and in accordance with the recommendations of the Somavert® (pegvisomant) Package Insert (US) or Somavert® (pegvisomant)

Who is Eligible

Genders:
- Men
- Women
Races:
- White
- African American
- Asian
- American Indian or Alaska Native
- Native Hawaiian or Pacific Islander
- Other
All Ethnicities
Ages 18 - 80

Eligibility Criteria

Subjects will be asked to take part in this study if they have a diagnosis of acromegaly a condition caused by too much growth hormone and they are or will be treated with Somavert (also called pegvisomant)

What is involved

The type of information that will be collected will include
But not be limited to
Background information about subjects
Such as birth date
Medical history
Ethnic origin
Treatments
Height and weight
And certain other medical information which will be collected as part of your routine care. Subjects will also be asked to complete questionnaires about their health and general well-being. This research study will also collect information about standard of care blood test results. Subjects will not need to have any special tests or additional procedures because they are taking part in this research study.